Related references
Note: Only part of the references are listed.Complications after frame-based stereotactic brain biopsy: a systematic review
Maximilien Riche et al.
NEUROSURGICAL REVIEW (2021)
The TeloDIAG: how telomeric parameters can help in glioma rapid diagnosis and liquid biopsy approaches
P. Billard et al.
ANNALS OF ONCOLOGY (2021)
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Michael Weller et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Blood-Based Detection of BRAF V600E in Gliomas and Brain Tumor Metastasis
Keiko M. Kang et al.
CANCERS (2021)
Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers
Timothy V. Pham et al.
GENOME MEDICINE (2021)
Evidence-based recommendations on categories for extent of resection in diffuse glioma
Philipp Karschnia et al.
EUROPEAN JOURNAL OF CANCER (2021)
PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression
Jonathan Weller et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas
Yao Yu et al.
NEURO-ONCOLOGY (2021)
Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences
Stefanie Lietke et al.
CANCERS (2021)
Low Detection Rate of H3K27M Mutations in Cerebrospinal Fluid Obtained from Lumbar Puncture in Newly Diagnosed Diffuse Midline Gliomas
Jotaro On et al.
DIAGNOSTICS (2021)
Fragmentation patterns and personalized sequencing of cell-free DNA in urine and plasma of glioma patients
Florent Mouliere et al.
EMBO MOLECULAR MEDICINE (2021)
Clinical outcomes as a function of the number of samples taken during stereotactic needle biopsies: a meta-analysis
Sanjay Dhawan et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives
Lidia Gatto et al.
ONCOLOGIST (2021)
Circulating Biomarkers in Glioblastoma Ready for Prime Time?
Dimitrios Mathios et al.
CANCER JOURNAL (2021)
TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study
M. Unterrainer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study
Kaspar Draaisma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Molecular imaging and advanced MRI findings following immunotherapy in patients with brain tumors
Norbert Galldiks et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma
Annette M. Molinaro et al.
JAMA ONCOLOGY (2020)
Mechanisms and therapeutic implications of hypermutation in gliomas
Mehdi Touat et al.
NATURE (2020)
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2020)
The integrated genomic and epigenomic landscape of brainstem glioma
Lee H. Chen et al.
NATURE COMMUNICATIONS (2020)
Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas
Mathias Kunz et al.
NEURO-ONCOLOGY (2019)
Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis
Verena Koerber et al.
CANCER CELL (2019)
The surgical perspective in precision treatment of diffuse gliomas
Niklas Thon et al.
ONCOTARGETS AND THERAPY (2019)
Defining EGFR amplification status for clinical trial inclusion
Pim J. French et al.
NEURO-ONCOLOGY (2019)
Increasing the diagnostic yield of stereotactic brain biopsy using intraoperative histological smear
Bertrand Mathon et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2019)
Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning
Bogdana Suchorska et al.
EUROPEAN JOURNAL OF CANCER (2019)
Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0
Ian Law et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Resection of gliomas deemed inoperable by neurosurgeons based on preoperative imaging studies
Derek G. Southwell et al.
JOURNAL OF NEUROSURGERY (2018)
DNA methylation-based classification of central nervous system tumours
David Capper et al.
NATURE (2018)
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
Bill H. Diplas et al.
NATURE COMMUNICATIONS (2018)
Response Assessment in Neuro-Oncology Clinical Trials
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors
Joerg Felsberg et al.
CLINICAL CANCER RESEARCH (2017)
Glioblastoma targeted therapy: updated approaches from recent biological insights
M. Touat et al.
ANNALS OF ONCOLOGY (2017)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas
Nathalie L. Albert et al.
NEURO-ONCOLOGY (2016)
Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics
Lindsey M. Hoffman et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2016)
Differentiating Radiation-Induced Necrosis from Recurrent Brain Tumor Using MR Perfusion and Spectroscopy: A Meta-Analysis
Ming-Tsung Chuang et al.
PLOS ONE (2016)
Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment
Hinke F. van Thuijl et al.
ACTA NEUROPATHOLOGICA (2015)
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Hideho Okada et al.
LANCET ONCOLOGY (2015)
Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas
Martin J. van den Bent et al.
NEURO-ONCOLOGY (2015)
Diagnostic Value and Safety of Brain Biopsy in Patients With Cryptogenic Neurological Disease: A Systematic Review and Meta-analysis of 831 Cases
Harrison Xiao Bai et al.
NEUROSURGERY (2015)
Comparative Effectiveness of Frame-Based, Frameless, and Intraoperative Magnetic Resonance Imaginge-Guided Brain Biopsy Techniques
Yi Lu et al.
WORLD NEUROSURGERY (2015)
Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients
Sabina Eigenbrod et al.
ACTA NEUROCHIRURGICA (2014)
Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
Brett E. Johnson et al.
SCIENCE (2014)
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma
Marc Remke et al.
ACTA NEUROPATHOLOGICA (2013)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Comparison of a Strategy Favoring Early Surgical Resection vs a Strategy Favoring Watchful Waiting in Low-Grade Gliomas
Asgeir S. Jakola et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Frameless robotically targeted stereotactic brain biopsy: feasibility, diagnostic yield, and safety
Kimon Bekelis et al.
JOURNAL OF NEUROSURGERY (2012)
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors
Andrew B. Lassman et al.
NEURO-ONCOLOGY (2011)
Hot spots in dynamic 18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas
M. Kunz et al.
NEURO-ONCOLOGY (2011)
Evaluation of brain biopsy in the diagnosis of severe neurologic disease of unknown etiology
Joseph D. Burns et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2009)
Stereotactic brain biopsy: Single center retrospective analysis of complications
Ching-Chang Chen et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2009)
Novel Molecular Stereotactic Biopsy Procedures Reveal Intratumoral Homogeneity of Loss of Heterozygosity of 1p/19q and TP53 Mutations in World Health Organization Grade II Gliomas
Niklas Thon et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2009)
Imaging of integrin αvβ3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography
Oliver Schnell et al.
NEURO-ONCOLOGY (2009)
Safety and efficacy of frameless and frame-based intracranial biopsy techniques
R. Dammers et al.
ACTA NEUROCHIRURGICA (2008)
Complications in 622 cases of frame-based stereotactic biopsy, a decreasing procedure
Paul N. Kongkham et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2008)
Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas
Eva M. Grasbon-Frodl et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Frameless image-guided stereotactic brain biopsy procedure: diagnostic yield, surgical morbidity, and comparison with the frame-based technique
GF Woodworth et al.
JOURNAL OF NEUROSURGERY (2006)
Stereotactic computed tomography-guided brain biopsy: diagnostic yield based on a series of 170 patients
MP Ferreira et al.
SURGICAL NEUROLOGY (2006)
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors
M Möllemann et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Share Paper
